Nemesis18,
So tell me, how does what you are doing because of what you went through help older rGBM patients that did not have a second resection event sooner than those who did have a second resection before receiving DCVax-L?; ). Hint: It doesn’t; ). Nothing you are doing here is helpful to those who can benefit from this treatment. In fact your logic supports the idea that what was learned about how this treatment is beneficial to some patient groups on its own, with additional insights added from other trials that a wider patient group can receive benefit from actuators and combos, should all be ignored so that those patient groups are left to suffer instead of having a chance at a longer term reprieve or even a cure. If you would have investigated this all more thoroughly instead of let your own pain get in the way you would have seen the error of your way. If allowable, I suggest you find a way to communicate with someone from the group of undeniable beneficiaries willing to discuss their journey with you, perhaps on a patient forum, or family of same to help you with this. Best wishes.
Market Data 
Markets 
AI
